TARA (Protara Therapeutics) ROCE % : -44.74% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Protara Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was -44.74%.

Protara Therapeutics ROCE % Historical Data

The historical data trend for Protara Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics ROCE % Chart

Protara Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-34.27

-24.70

-46.99

-48.36

-40.41

Protara Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-57.17	-70.00	-53.76	-54.36	-44.74

Protara Therapeutics ROCE % Calculation

Protara Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-49.154	/	( ( (78.954 - 6.149)	+	(181.454 - 10.961) )	/ 2 )
	=	-49.154	/	( (72.805	+	170.493)	/ 2 )
	=	-49.154	/	121.649
	=	-40.41 %

Protara Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-57.248	/	( ( (94.09 - 8.642)	+	(181.454 - 10.961) )	/ 2 )
	=	-57.248	/	( ( 85.448	+	170.493 )	/ 2 )
	=	-57.248	/	127.9705
	=	-44.74 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Protara Therapeutics (NAS:TARA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Protara Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Protara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1KPA:Germany

Address

345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010

Website

http://www.protaratx.com

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Executives

Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Jesse Shefferman	director, officer: CEO and President	C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry	officer: VP, Controller	345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari	officer: Chief Medical Officer	C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang	director	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo	officer: Chief Medical Officer	C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall	10 percent owner	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly	director	ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julio Casoy	officer: Chief Medical Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Jacqueline Zummo	officer: Sr. Vice President, Research	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014